-

08:09:48 AM

TELA Stock News

TELA - TELA Bio Inc

03/29/23 7:00 AM

Nasdaq : TELA

low float

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions

RHEA-AI

neutral

03/23/23 7:00 AM

Nasdaq : TELA

low float

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize

RHEA-AI

very positive

03/21/23 4:02 PM

Nasdaq : TELA

earningslow float

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own

RHEA-AI

neutral

03/16/23 7:00 AM

Nasdaq : TELA

clinical triallow float

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing

RHEA-AI

neutral

02/28/23 7:00 AM

Nasdaq : TELA

earningslow float

TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results

TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the

RHEA-AI

neutral

02/24/23 4:02 PM

Nasdaq : TELA

low float

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the

RHEA-AI

very positive

02/21/23 7:00 AM

Nasdaq : TELA

low float

TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques

TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by

RHEA-AI

very positive

02/14/23 7:00 AM

Nasdaq : TELA

low float

TELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization

TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced

RHEA-AI

very positive

01/20/23 4:05 PM

Nasdaq : TELA

low float

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the

RHEA-AI

very positive

01/09/23 7:00 AM

Nasdaq : TELA

low float

TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds

TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

TELA Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.telabio.com
Security nameTELA Bio Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees123
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing

About TELA Bio Inc

TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to providing patients with advanced, economically effective biologic material repair solutions to patients to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.